Literature DB >> 9345654

New insulins and other possible therapeutic approaches.

J Johannesen1, K F Petersen, M Berger, C Binder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9345654     DOI： 10.1007/bf03168195

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  9 in total

1.  Insulin lispro in CSII: results of a double-blind crossover study.

Authors:  B Zinman; H Tildesley; J L Chiasson; E Tsui; T Strack
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

2.  Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

Authors:  O G Kolterman; S Schwartz; C Corder; B Levy; L Klaff; J Peterson; A Gottlieb
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

3.  Ultrasound-mediated transdermal protein delivery.

Authors:  S Mitragotri; D Blankschtein; R Langer
Journal:  Science       Date:  1995-08-11       Impact factor: 47.728

4.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

5.  Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity.

Authors:  A A Young; M W Wang; B Gedulin; T J Rink; R Pittner; K Beaumont
Journal:  Metabolism       Date:  1995-12       Impact factor: 8.694

Review 6.  C-peptide revisited--new physiological effects and therapeutic implications.

Authors:  J Wahren; B L Johansson; H Wallberg-Henriksson; B Linde; E Fernqvist-Forbes; J R Zierath
Journal:  J Intern Med       Date:  1996-09       Impact factor: 8.989

Review 7.  Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus.

Authors:  D B Dunger; T D Cheetham; E C Crowne
Journal:  Metabolism       Date:  1995-10       Impact factor: 8.694

8.  Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes.

Authors:  A C Moses; S C Young; L A Morrow; M O'Brien; D R Clemmons
Journal:  Diabetes       Date:  1996-01       Impact factor: 9.461

9.  Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A.

Authors:  P D Zenobi; Y Glatz; A Keller; S Graf; S E Jaeggi-Groisman; W F Riesen; E J Schoenle; E R Froesch
Journal:  Eur J Endocrinol       Date:  1994-09       Impact factor: 6.664
  9 in total
  1 in total

Review 1.  Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.

Authors:  A Evans; A J Krentz
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.